ORION CORP.B UNSP.ADR 1/2 (OFK0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ORION CORP.B UNSP.ADR 1/2 (OFK0) has a cash flow conversion efficiency ratio of 0.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€37.00 Million ≈ $43.26 Million USD) by net assets (€1.12 Billion ≈ $1.31 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ORION CORP.B UNSP.ADR 1/2 market capitalisation for the company's overall valuation and market capitalisation.
ORION CORP.B UNSP.ADR 1/2 - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how ORION CORP.B UNSP.ADR 1/2's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ORION CORP.B UNSP.ADR 1/2 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ORION CORP.B UNSP.ADR 1/2 ranked by their cash flow conversion efficiency. Explore ORION CORP.B UNSP.ADR 1/2 cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
InterDigital Inc
NASDAQ:IDCC
|
0.069x |
|
SAINSBURY -J.- ADR/4 NEW
F:SUY
|
N/A |
|
SPIE SA
PA:SPIE
|
0.362x |
|
Tripod Technology Corp
TW:3044
|
0.058x |
|
GETLINK ADR EO-40
F:TNU
|
N/A |
|
Xpeng Inc
NYSE:XPEV
|
0.004x |
|
Merlin Properties SOCIMI SA
LS:MRL
|
N/A |
|
China Minmetals Rare Earth Co Ltd
SHE:000831
|
0.033x |
Annual Cash Flow Conversion Efficiency for ORION CORP.B UNSP.ADR 1/2 (2022–2025)
The table below shows the annual cash flow conversion efficiency of ORION CORP.B UNSP.ADR 1/2 from 2022 to 2025. View ORION CORP.B UNSP.ADR 1/2 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.28 Billion ≈ $1.50 Billion |
€316.80 Million ≈ $370.37 Million |
0.247x | -15.52% |
| 2024-12-31 | €1.00 Billion ≈ $1.17 Billion |
€293.40 Million ≈ $343.02 Million |
0.292x | +118.37% |
| 2023-12-31 | €890.10 Million ≈ $1.04 Billion |
€119.00 Million ≈ $139.12 Million |
0.134x | -72.05% |
| 2022-12-31 | €908.10 Million ≈ $1.06 Billion |
€434.40 Million ≈ $507.86 Million |
0.478x | -- |
About ORION CORP.B UNSP.ADR 1/2
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more